Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase I of 89Zr-girentuximab (89Zr-TLX250) to Assess the Safety, Biodistribution, Pharmacokinetics and Sensitivity/Specificity of PET/CT Images in Patients With Suspected Renal Cell Carcinoma Including Clear Cell Renal Cell Carcinoma (ZIRDAC-JP Study)

NCT04496089 is registered in ClinicalTrials.gov with Telix Pharmaceuticals (Innovations) Pty Limited as lead sponsor.

NCT NCT04496089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04496089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase I of 89Zr-girentuximab (89Zr-TLX250) to Assess the Safety, Biodistribution, Pharmacokinetics and Sensitivity/Specificity of PET/CT Images in Patients With Suspected Renal Cell Carcinoma Including Clear Cell Renal Cell Carcinoma (ZIRDAC-JP Study)
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Phase
Phase 1
Overall status
Completed
Start date
August 1, 2020
Completion date
April 6, 2021
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell, clear cell renal cell carcinoma